Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma. Issue 1 (4th August 2020)

• Record Type: Journal Article
• Authors: Zhao, Xiaoxian; Bodo, Juraj; Chen, Ruoying; Durkin, Lisa; Souers, Andrew J.; Phillips, Darren C.; Hsi, Eric D.
• Is Part Of: EJHaem. Volume 1:Issue 1(2020)
• Page Start: 161
• Page End: 169
• Publication Date: 2020-08-04
• Subjects: CDK9 inhibitor -- mantle cell lymphoma -- MCL‐1 -- venetoclax; Hematology -- Periodicals; 616.15
• DOI: 10.1002/jha2.48
• Languages: English
• ISSNs: 2688-6146

Abstract

Abstract: Mantle cell lymphoma (MCL) is an aggressive and largely incurable subtype of non‐Hodgkin's lymphoma. Venetoclax has demonstrated efficacy in MCL patients with relapsed or refractory disease, however response is variable and less durable than CLL. This may be the result of co‐expression of other anti‐apoptotic proteins such as MCL‐1, which is associated with both intrinsic and acquired resistance to venetoclax in B‐cell malignancies. One strategy for neutralizing MCL‐1 and other short‐lived survival factors is to inhibit CDK9, which plays a key role in transcription. Here, we report the response of MCL cell lines and primary patient samples to the combination of venetoclax and novel CDK9 inhibitors. Primary samples represented de novo patients and relapsed disease, including relapse after ibrutinib failure. Despite the diverse responses to each single agent, possibly due to variable expression of the BCL‐2 family members, venetoclax plus CDK9 inhibitors synergistically induced apoptosis in MCL cells. The synergistic effect was also confirmed via venetoclax plus a direct MCL‐1 inhibitor. Murine xenograft studies demonstrated potent in vivo efficacy of venetoclax plus CDK9 inhibitor that was superior to each agent alone. Together, this study supports clinical investigation of this combination in MCL, including in patients who have progressed on ibrutinib.